Lung Cancers Today Videos
Stephen Liu, MD, shares his insights on the recent approval, the data behind it, and what the future may hold. Jennifer Carlisle, MD, shares her institution’s experience with outpatient administration of the bispecific T-cell ... Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic. Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes. The study participants include those who have had at least one first-degree relative diagnosed with lung cancer. Sophie Poznanski, PhD, shares insights from her ASCO 2025 presentation on the multifunctional antibody modality. The study compared results from North America with global results by high-income and low- or middle-income countries. Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025. Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups. Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025. Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting. Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025. Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together. Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting. Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting. Eric Singhi, MD, discusses the recent FDA approval and explains the associated new biomarker testing considerations. Mara Antonoff, MD, explains the nuances of determining if a patient with oligometastatic disease is a candidate for surgery. Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions. Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones. Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.